Selpercatinib Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 40 mg, 80 mg, 160 mg

Reference Brands: Retevmo (USA)

Category: Oncology Cancer Care

Selpercatinib is available in Capsules and strengths such as 40 mg, 80 mg, 160 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Selpercatinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Selpercatinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Selpercatinib is an oral targeted therapy used for the treatment of cancers with specific RET gene alterations and is marketed under the brand name Retevmo. It is indicated for adults with RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancers, as well as for children aged 2 years and older with certain solid tumors harboring RET alterations. Treatment with selpercatinib requires prior confirmation of a RET gene mutation or fusion through laboratory genetic testing.

Selpercatinib is a selective tyrosine kinase inhibitor that works by blocking the activity of RET proteins produced by abnormal RET genes. By inhibiting these signaling pathways, it prevents cancer cells from growing and dividing, thereby slowing tumor progression. Its targeted mechanism allows for precise therapy in patients whose cancers are driven by RET alterations, minimizing effects on normal cells.

Taken orally in capsule form, selpercatinib offers a convenient administration route while providing a precision oncology approach. It is being studied for other types of RET-driven cancers as well, expanding its potential use. Selpercatinib represents an important option in the personalized treatment of cancers driven by RET gene abnormalities.